Armenta Ltd.
- Home
- Companies
- Armenta Ltd.
- Products
- Armenta - Model APT-X - Acoustic Pulse ...
Armenta - Model APT-X -Acoustic Pulse Technology (APT)
FromArmenta Ltd.
APT-X is Armenta’s revolutionary Acoustic Pulse Technology (APT) solution for mitigating mastitis in dairy cattle. Used directly on a dairy cow’s udder, fighting the infection and inflammation quickly, easily, and cost-effectively.
Most popular related searches
- Lightweight
- Hand-Held
- Mobile
- Simple to use
- Easy set-up in every farm
- Powered by compressed air
- Patent protected
- Covers large treatment area
- APT-X Hand-Held device - Based on Acoustic Pulse Technology (APT)
- Air Tank – Allows treating up to 10-12 cows prior to refill (to be acquired separately from authorized supplier)
- Control Unit - Provides a digital display of the information needed for treatment management
- Applicator Module (AM) – The APT-X’s consumable, customized to suit your herd size
Before using the APT-X, Identify the infected cow by high somatic cell count in the milk or visible signs of infection. The infected quarter is to be identified by using the California Mastitis Test (CMT).
- Generously applying the ultrasound gel on the skin of the infected quarter and to the tip of the Applicator Module (AM).
- Holding the APT-X against the surface of the area to be treated, facing upwards.
- Applying the acoustic pulses according to Armenta’s Treatment Protocol.
Armenta’s trajectory is one of ongoing growth. The company continues to develop alternative therapies to treat inflammatory diseases affecting herd health and farm profitability, as well as leading the efforts to prevent the spread of antibiotic resistance (AMR).
Expanding the use of APT-based solutions
- Dry-Period therapy
- Treating reproductive disorders and lameness among cattle.
- Herd health management among other livestock, such as sheep, goats and pigs.
EcoMilk StationAutomated and streamlined APT treatment for large farms.
- An innovative treatment station, where the animal is gently restrained.
- APT treatment is automatically initiated on all four quarters at the same time.
- This project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No 946330.
